Search

Author/Creator Ruefer, Axel

1. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial. (16th December 2016)

Authors:
Mey, Ulrich J. M.; Brugger, Wolfram; Schwarb, Heike; Pederiva, Stefanie; Schwarzer, Andreas; Dechow, Tobias; Jehner, Paul; Rauh, Jacqueline; Taverna, Christian J.; Schmid, Mathias; Schmidt‐Hieber, Martin; Doerfel, Steffen; Fischer, Natalie; Ruefer, Axel; Ziske, Carsten; Knauf, Wolfgang; Cathomas,...
Journal:
British journal of haematology
Issue:
Volume 176:Number 5(2017)
Page Start:
770
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma. Issue 6 (June 2015)

Authors:
Berger, Martin D.; Branger, Giacomo; Leibundgut, Kurt; Baerlocher, Gabriela M.; Seipel, Katja; Mueller, Beatrice U.; Gregor, Michael; Ruefer, Axel; Pabst, Thomas
Journal:
Leukemia research
Issue:
Volume 39:Issue 6(2015:Jun.)
Page Start:
561
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. (February 2017)

Authors:
Bonadies, Nicolas; Feller, Anita; Rovo, Alicia; Ruefer, Axel; Blum, Sabine; Gerber, Bernhard; Stuessi, Georg; Benz, Rudolf; Cantoni, Nathan; Holbro, Andreas; Schmidt, Adrian; Lehmann, Thomas; Wilk, C. Matthias; Arndt, Volker
Journal:
Cancer epidemiology
Issue:
Volume 46(2017:Feb.)
Page Start:
85
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗